Year: 2020

SANTA BARBARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — AppFolio, Inc. (NASDAQ: APPF) (“AppFolio” or the “Company”), a leading provider of cloud-based business software solutions, services, and data analytics to the real estate vertical today announced its financial results for the third quarter ended September 30, 2020.AppFolio’s operating results for the third quarter of 2020 are summarized in the tables accompanying this press release. The Company nevertheless urges investors to read its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (the “SEC”) on March 2, 2020, as well as its more detailed third quarter 2020 results that will be included in the Company’s Quarterly Report on Form 10-Q, which will be filed with the SEC today. These periodic...

– Comparable Portfolio Occupancies Improve Sequentially During Q3 –– Hotel and Corporate Cash Burn Rates Better than Forecasted –– 37 of the Company’s 39 Wholly-Owned Hotels Operational –PHILADELPHIA, Nov. 09, 2020 (GLOBE NEWSWIRE) — Hersha Hospitality Trust (NYSE: HT) (“Hersha,” “Company,” “we” or “our”), owner of high-quality upscale and lifestyle hotels in urban gateway markets and resort destinations, today announced results for the third quarter ended September 30, 2020.Third Quarter 2020 Financial ResultsNet loss applicable to common shareholders was approximately ($49.2 million), or ($1.27) per diluted common share, in the third quarter 2020, compared to net loss applicable to common shareholders of approximately ($5.4 million), or ($0.15) per diluted common share, in the third quarter...

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), a media and consumer products company, today announced that it will report its third quarter 2020 financial results after the market closes on November 12, 2020. The Company will hold a conference call with the investment community at 5:00 p.m. Eastern Time that day.A webcast of the conference call will be available live on the Investor Relations section of Xcel’s website at https://www.xcelbrands.com/. Interested parties unable to access the conference call via the webcast may dial 877-300-8521. A replay of the conference call will be available on the Company website for approximately two weeks following the event and can be accessed at 8445122921 using replay pin number 10149912.About Xcel BrandsXcel Brands, Inc. (NASDAQ:XELB)...

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — EverQuote, Inc. (“EverQuote”), a leading online marketplace for insurance shopping, today announced that management will present and host one-on-one investor meetings at the following investor conferences:RBC Global Technology, Internet, Media, and Telecommunications Virtual ConferenceDate: Tuesday, November 17, 2020Virtual Fireside Chat Time: 10:40 a.m. ETRaymond James Technology Investors ConferenceDate: Monday, December 7, 2020Virtual Fireside Chat Time: 5:00 p.m. ETUBS Technology ConferenceDate: Tuesday, December 8, 2020Virtual Fireside Chat Time: 8:25 a.m. ETConference fireside chats will be available via live audio webcast and archived replay on EverQuote’s investor relations website at http://investors.everquote.com.About EverQuoteEverQuote operates a leading online insurance...

FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that its VERSATILE-002 Phase 2 clinical trial evaluating the combination of PDS0101 and KEYTRUDA® (pembrolizumab) for the first-line treatment of head and neck cancer that has returned or spread is now open. The trial is being conducted in collaboration with Merck.The VERSATILE-002 Phase 2 trial is a multi-center, open label, single arm, non-randomized trial that plans to enroll approximately 100 patients across 25 sites in the U.S. The University of Tennessee Medical Center is the first site to open. The studies to be performed at the...

Reports record Breast Products net sales of $15.3 million, representing 54% sequential growth and 21% year over year growthResults driven by U.S. recovery and market outperformance in the core breast products segmentSANTA BARBARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced its financial results for the third quarter ended September 30, 2020.Jeff Nugent, Sientra’s Chairman and Chief Executive Officer, said, “Sientra recorded exceptional results in Q3, posting 54% sequential quarter over quarter sales growth from Q2’20, despite the strong headwinds our business and the industry have faced from COVID-19.   The third quarter represented significant improvement in net sales in our Breast Products segment. Our pivot to focus...

SCOTTSDALE, Ariz., Nov. 09, 2020 (GLOBE NEWSWIRE) — AgJunction Inc. (TSX: AJX) (“AgJunction” or the “Company”) is reporting financial results for the third quarter ended September 30, 2020. All currency amounts are expressed in U.S. dollars.Third Quarter 2020 Financial Highlights vs. Third Quarter 2019Revenue was $3.8 million versus $8.6 million (Q3 2019 included $5.5 million of revenue related to the Bulk Purchase Order (BPO)).Gross margin increased significantly to 49.7% compared to 32.3%.Operating expenses improved to $2.7 million compared to $5.3 million.Net loss improved to $(0.9) million or $(0.01) per share, versus a net loss of $(2.5) million or $(0.02) per share.EBITDA improved to $(0.2) million versus $(1.9) million.Management Commentary“Throughout the third quarter, we continued to make good progress...

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three and nine months ended September 30, 2020 and provided an update on key initiatives.Recent EventsAs previously announced on October 29, 2020, Tricida completed an End-of-Review Type A meeting with the FDA on October 20, 2020, that followed a Complete Response Letter (CRL) that was received by the company on August 21, 2020 for the veverimer New Drug Application (NDA) that was under review by the U.S. Food and Drug Administration (FDA) through...